Utilization of TAS-102 (TAS) or regorefenib (Rego) among commercially insured refractory metastatic colorectal cancer (R-mCRC) patients.

被引：0
|
作者：
Zheng, Hanke
Yu, Tianzhou
Romley, John
Barzi, Afsaneh
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
[2] City Hope AccessHope, Med Oncol & Therapeut, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23121
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
    Conti, Matteo
    Bolzacchini, Elena
    Luchena, Giovanna
    Bertu', Lorenza
    Tagliabue, Paola
    Aglione, Stefania
    Ardizzoia, Antonio
    Arnoffi, Jessica
    Guida, Francesco Maria
    Bertolini, Alessandro
    Pastorini, Alessandro
    Duro, Maria
    Bettega, Donato
    Roda', Giovambattista
    Artale, Salvatore
    Squizzato, Alessandro
    Giordano, Monica
    CANCERS, 2023, 15 (13)
  • [22] Efficacy and safety of regorafenib compared to TAS-102 for refractory metastatic colorectal cancer
    Abrahao, Ana Beatriz Kinupe
    Ko, Yoo-Joung
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Therapeutic effect of TAS-102 (A) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy by the Kohne model (Km).
    Nishina, Tomohiro
    Yoshino, Takayuki
    Mizunuma, Nobuyuki
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Baba, Hideo
    Tsuji, Akihito
    Yamaguchi, Kensei
    Muro, Kei
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [24] Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Lee S. Rosen
    Robert J. Mayer
    Jonathan W. Goldman
    Jeffrey R. Infante
    Fabio Benedetti
    Donghu Lin
    Hirokazu Mizuguchi
    Christopher Zergebel
    Manish R. Patel
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 439 - 439
  • [25] Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies
    Sueda, Toshinori
    Sakai, Daisuke
    Kudo, Toshihiro
    Sugiura, Takashi
    Takahashi, Hidekazu
    Haraguchi, Naotsugu
    Nishimura, Junichi
    Hata, Taishi
    Hayashi, Taro
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    Satoh, Taroh
    ANTICANCER RESEARCH, 2016, 36 (08) : 4299 - 4306
  • [26] TAS-102 in metastatic colorectal cancer (mCRC) - predictive and prognostic factors in a European patient population
    Obermannova, Radka
    Grell, Peter
    Dvorak, Josef
    Vocka, Michal
    John, Stanislav
    Tuskova, Helena
    Buchler, Tomas
    Petruzelka, Lubos
    Vyzula, Rostislav
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer.
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Komori, Azusa
    Kito, Yosuke
    Mitani, Seiichiro
    Hasegawa, Hiroko
    Narita, Yukiya
    Kadowaki, Shigenori
    Ura, Takashi
    Ando, Masashi
    Mori, Keita
    Tajika, Masahiro
    Yasui, Hirofumi
    Muro, Kei
    Yamazaki, Kentaro
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [28] Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
    Chen, Duke
    Wu, Yu-Shen
    Lin, Huapeng
    Wang, Yihan
    Li, Longhao
    Zhang, Tao
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 2915 - 2924
  • [29] COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AND TAS-102 IN REFRACTORY METASTATIC COLORECTAL CANCER
    Cho, S. K.
    Hay, J. W.
    Barzi, A.
    VALUE IN HEALTH, 2018, 21 : S1 - S1
  • [30] TAS-102 plus bevacizumab in metastatic colorectal cancer Reply
    Pfeiffer, Per
    Moller, Soren
    Winther, Stine Braendegaard
    Qvortrup, Camilla
    LANCET ONCOLOGY, 2020, 21 (05): : E227 - E227
12345